Vanderkerken K - Search Results

1

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.

Fan R, Satilmis H, Vandewalle N, Verheye E, Vlummens P, Maes A, Muylaert C, De Bruyne E, Menu E, Evans H, Chantry A, De Beule N, Hose D, Törngren M, Eriksson H, Vanderkerken K, Maes K, Breckpot K, De Veirman K. Fan R, et al. Among authors: vanderkerken k. J Immunother Cancer. 2023 Jan;11(1):e005319. doi: 10.1136/jitc-2022-005319. J Immunother Cancer. 2023. PMID: 36650020 Free PMC article.

2

The F-actin content of multiple myeloma cells as a measure of their migration.

Menu E, Braet F, Timmers M, Van Riet I, Van Camp B, Vanderkerken K. Menu E, et al. Among authors: vanderkerken k. Ann N Y Acad Sci. 2002 Nov;973:124-36. doi: 10.1111/j.1749-6632.2002.tb04620.x. Ann N Y Acad Sci. 2002. PMID: 12485848

3

Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.

Asosingh K, Menu E, Van Valckenborgh E, Vande Broek I, Van Riet I, Van Camp B, Vanderkerken K. Asosingh K, et al. Among authors: vanderkerken k. Clin Exp Metastasis. 2002;19(7):583-91. doi: 10.1023/a:1020987830132. Clin Exp Metastasis. 2002. PMID: 12498387

4

Selective in vivo growth of lymphocyte function- associated antigen-1-positive murine myeloma cells. Involvement of function-associated antigen-1-mediated homotypic cell-cell adhesion.

Asosingh K, Vankerkhove V, Van Riet I, Van Camp B, Vanderkerken K. Asosingh K, et al. Among authors: vanderkerken k. Exp Hematol. 2003 Jan;31(1):48-55. doi: 10.1016/s0301-472x(02)00970-0. Exp Hematol. 2003. PMID: 12543106 Free article.

5

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B, Croucher P. Vanderkerken K, et al. Cancer Res. 2003 Jan 15;63(2):287-9. Cancer Res. 2003. PMID: 12543775

6

Delayed in vivo disease progression is associated with high proportions of CD45+ myeloma cells in the 5T2MM murine model.

Asosingh K, Willems A, Van Riet I, Van Camp B, Vanderkerken K. Asosingh K, et al. Among authors: vanderkerken k. Cancer Res. 2003 Jun 15;63(12):3019-20. Cancer Res. 2003. PMID: 12810619

7

Multiple myeloma biology: lessons from the 5TMM models.

Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Vanderkerken K, et al. Immunol Rev. 2003 Aug;194:196-206. doi: 10.1034/j.1600-065x.2003.00035.x. Immunol Rev. 2003. PMID: 12846816 Review.

8

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.

Asosingh K, De Raeve H, Menu E, Van Riet I, Van Marck E, Van Camp B, Vanderkerken K. Asosingh K, et al. Among authors: vanderkerken k. Blood. 2004 Apr 15;103(8):3131-7. doi: 10.1182/blood-2003-08-2946. Epub 2003 Nov 26. Blood. 2004. PMID: 15070695 Free article.

9

Myeloma cells (5TMM) and their interactions with the marrow microenvironment.

Menu E, Asosingh K, Van Riet I, Croucher P, Van Camp B, Vanderkerken K. Menu E, et al. Among authors: vanderkerken k. Blood Cells Mol Dis. 2004 Sep-Oct;33(2):111-9. doi: 10.1016/j.bcmd.2004.04.012. Blood Cells Mol Dis. 2004. PMID: 15315788 Review.

10

Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.

Van Valckenborgh E, Croucher PI, De Raeve H, Carron C, De Leenheer E, Blacher S, Devy L, Noël A, De Bruyne E, Asosingh K, Van Riet I, Van Camp B, Vanderkerken K. Van Valckenborgh E, et al. Among authors: vanderkerken k. Am J Pathol. 2004 Sep;165(3):869-78. doi: 10.1016/S0002-9440(10)63349-4. Am J Pathol. 2004. PMID: 15331411 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

193 results

Search Page